scispace - formally typeset
Open AccessJournal ArticleDOI

Tumor suppressor properties of the splicing regulatory factor RBM10.

TLDR
The previous and current results reveal that RBM10 is a tumor suppressor that represses Notch signaling and cell proliferation through the regulation of NUMB alternative splicing.
Abstract
RBM10 is an RNA binding protein and alternative splicing regulator frequently mutated in lung adenocarcinomas. Recent results indicate that RBM10 inhibits proliferation of lung cancer cells by promoting skipping of exon 9 of the gene NUMB, a frequent alternative splicing change in lung cancer generating a negative regulator of Notch signaling. Complementing these observations, we show that knock down of RBM10 in human cancer cells enhances growth of mouse tumor xenografts, confirming that RBM10 acts as a tumor suppressor, while knock down of an oncogenic mutant version of RBM10 reduces xenograft tumor growth. A RBM10 mutation found in lung cancer cells, V354E, disrupts RBM10-mediated regulation of NUMB alternative splicing, inducing the cell proliferation-promoting isoform. We now show that 2 natural RBM10 isoforms that differ by the presence or absence of V354 in the second RNA Recognition Motif (RRM2), display similar regulatory effects on NUMB alternative splicing, suggesting that V354E actively disrupts RBM10 activity. Structural modeling localizes V354 in the outside surface of one α-helix opposite to the RNA binding surface of RBM10, and we show that the mutation does not compromise binding of the RRM2 domain to NUMB RNA regulatory sequences. We further show that other RBM10 mutations found in lung adenocarcinomas also compromise regulation of NUMB exon 9. Collectively, our previous and current results reveal that RBM10 is a tumor suppressor that represses Notch signaling and cell proliferation through the regulation of NUMB alternative splicing.

read more

Citations
More filters
Journal ArticleDOI

RNA splicing factors as oncoproteins and tumour suppressors

TL;DR: The recent genomic characterization of cancers has revealed recurrent somatic point mutations and copy number changes affecting genes encoding RNA splicing factors, which may create novel vulnerabilities in cancer cells that can be therapeutic exploited using compounds that can influence the splicing process.
Journal ArticleDOI

RNA-Binding Proteins in Cancer: Old Players and New Actors

TL;DR: Evidence that RBPs modulate multiple cancer traits, emphasize their functional diversity, and assess future trends in the study of RBPs in cancer are reviewed.
Journal ArticleDOI

Roles and mechanisms of alternative splicing in cancer - implications for care.

TL;DR: Antisense oligonucleotides offer promise to modulate cancer-relevant alternative splicing decisions, with proof of concept for this type of therapy demonstrated by Nusinersen, a first-in-class treatment for patients with spinal muscular atrophy.
Journal ArticleDOI

RNA-binding proteins in human genetic disease.

TL;DR: The authors review the role of RBPs in human genetic disorders, both Mendelian and somatic, discuss the molecular mechanisms of disease and highlight emerging therapeutic interventions that target RBPs.
Journal ArticleDOI

Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types.

TL;DR: Analysis of whole-exome sequencing data across 33 tumor types in The Cancer Genome Atlas suggests that somatic alteration of genes involved in the RNA-splicing process is common in cancer and may represent an underappreciated hallmark of tumorigenesis.
References
More filters
Journal ArticleDOI

COSMIC: exploring the world's knowledge of somatic mutations in human cancer

TL;DR: COSMIC, the Catalogue Of Somatic Mutations In Cancer is the world's largest and most comprehensive resource for exploring the impact of somatic mutations in human cancer, describing 2 002 811 coding point mutations in over one million tumor samples and across most human genes.
Journal ArticleDOI

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing

TL;DR: Exome and genome sequences and whole-genome sequence analysis revealed frequent structural rearrangements, including in-frame exonic alterations within EGFR and SIK2 kinases, which are attractive targets for biological characterization and therapeutic targeting of lung adenocarcinoma.
Journal ArticleDOI

The gene encoding the splicing factor SF2/ASF is a proto-oncogene

TL;DR: It is found that the splicing factor SF2/ASF is upregulated in various human tumors, in part due to amplification of its gene, SFRS1, and can act as an oncoprotein and is a potential target for cancer therapy.
Journal ArticleDOI

Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged

TL;DR: Emerging insights into this process indicate that pathways that are frequently deregulated in cancer often play important roles in promoting aberrant splicing, which in turn contributes to all aspects of tumor biology.
Journal ArticleDOI

Alterations of the Notch pathway in lung cancer

TL;DR: It is shown that Notch signaling is altered in approximately one third of non–small-cell lung carcinomas (NSCLCs), which are the leading cause of cancer-related deaths, and it is suggested that it might represent a possible target for molecular therapies in these tumors.
Related Papers (5)

Comprehensive molecular profiling of lung adenocarcinoma: The cancer genome atlas research network

Eric A. Collisson, +318 more
- 01 Jan 2014 -